The purchase is too small relative to market cap to signal material conviction. Monitor for additional insider buying or a C-suite purchase to confirm a bullish signal.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 6 $7.64entry
- T+1 · 8d ago −1.11%α −3.48% · $7.55
- T+5 · 4d ago −16.70%α −19.29% · $6.36
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director David R. Epstein purchased 15,000 shares of AgomAb Therapeutics for $104K in three open-market trades on November 5, 2026, with no 10b5-1 plan. The total value represents 0.03% of the company's $337M market cap, a trivial amount relative to company size.
Key Financial Metrics
Key Facts
- Director David R. Epstein bought 15,000 shares total in three open-market trades on November 5, 2026
- Total purchase value: $104K (0.03% of $337M market cap)
- All trades were open-market purchases (Form 4 code P) with no 10b5-1 plan
- Buyer is a Director, not C-suite (CEO/CFO)
Financial Impact
$104K total insider purchase, 0.03% of market cap
Risk Factors
- Purchase value is trivial relative to market cap (0.03%), limiting signaling value
- Buyer is a Director, not a C-suite executive, reducing informational weight
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| INSIDER-BUY Data (Synthetic) | 0001445826-26-000018 |
Track record
16 reports on AGMB
5 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +6.98% at T+5 after the Apr 24, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 16, 2026today Insider Buy Neutral 3/10 Entry $6.36 Now $5.97 −6.13% settles Nov 23
- Nov 6, 202610d ago Insider Buy Neutral 2/10 Viewing Entry $7.64 to $6.36 Now $5.97 −21.81% ▼ −16.70% −19.29% vs SPY
- Oct 22, 202625d ago Insider Buy Bullish 4/10 Entry $9.26 to $7.95 Now $5.97 −35.53% ▼ −14.15% −14.85% vs SPY
- Oct 13, 20264w ago 6-K Bullish 5/10 Entry $8.69 to $9.11 Now $5.97 −31.30% ▲ +4.83% +4.38% vs SPY
- Oct 13, 20264w ago Press Release Bullish 6/10 Entry $8.69 to $9.11 Now $5.97 −31.30% ▲ +4.83% +4.38% vs SPY
- Oct 1, 20266w ago 6-K Bullish 7/10 Entry $8.65 to $9.22 Now $5.97 −30.98% ▲ +6.59% +5.29% vs SPY
- Oct 1, 20266w ago Press Release Bullish 7/10 Entry $8.65 to $9.22 Now $5.97 −30.98% ▲ +6.59% +5.29% vs SPY
- Sep 14, 20269w ago 6-K Bullish 7/10 Entry $12.16 to $11.49 Now $5.97 −50.90% ▼ −5.51% −7.64% vs SPY
- Sep 14, 20269w ago Press Release Bullish 6/10 Entry $12.16 to $11.49 Now $5.97 −50.90% ▼ −5.51% −7.64% vs SPY
- Sep 11, 20269w ago 6-K Neutral 2/10 Entry $12.28 to $11.70 Now $5.97 −51.38% ▼ −4.72% −4.83% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers